Literature DB >> 11316634

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps.

R J O'Brien1, P P Nunn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11316634     DOI： 10.1164/ajrccm.163.5.2007122

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  37 in total

1.  Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

3.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

4.  Study of interactions between Mycobacterium tuberculosis proteins: SigK and anti-SigK.

Authors:  Vasavi Malkhed; Bargavi Gudlur; Bhargavi Kondagari; Ramasree Dulapalli; Uma Vuruputuri
Journal:  J Mol Model       Date:  2010-07-31       Impact factor: 1.810

5.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 6.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Crystallization and preliminary X-ray diffraction analysis of biotin acetyl-CoA carboxylase ligase (BirA) from Mycobacterium tuberculosis.

Authors:  Vibha Gupta; Rakesh K Gupta; Garima Khare; Avadhesha Surolia; Dinakar M Salunke; Anil K Tyagi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-05-23

8.  In vitro antituberculosis activity of diterpenoids from the Vietnamese medicinal plant Croton tonkinensis.

Authors:  Woong Sik Jang; Md Anirban Jyoti; Sukyung Kim; Kung-Woo Nam; Thi Kim Quy Ha; Won Keun Oh; Ho-Yeon Song
Journal:  J Nat Med       Date:  2015-09-19       Impact factor: 2.343

9.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC).

Authors:  Sharmila Sivendran; Victoria Jones; Dianqing Sun; Yi Wang; Anna E Grzegorzewicz; Michael S Scherman; Andrew D Napper; J Andrew McCammon; Richard E Lee; Scott L Diamond; Michael McNeil
Journal:  Bioorg Med Chem       Date:  2009-11-20       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.